Loading clinical trials...
Loading clinical trials...
A Phase II, Randomized, Double-Blind, Placebo-Controlled Multicenter Study to Assess the Efficacy and Safety of MSTT1041A in Patients With Moderate to Severe Atopic Dermatitis
Conditions
Interventions
MSTT1041A
Placebo
Locations
21
United States
Alabama Allergy & Asthma
Birmingham, Alabama, United States
California Allergy and Asthma Medical Group - CRN
Los Angeles, California, United States
Jonathan Corren MD, Inc.
Los Angeles, California, United States
Asthma & Allergy; Associates, P.C.
Colorado Springs, Colorado, United States
South Coast Research Center, Inc.
Miami, Florida, United States
Harmony Clinical Research, Inc
North Miami Beach, Florida, United States
Start Date
February 6, 2019
Primary Completion Date
March 11, 2020
Completion Date
May 5, 2020
Last Updated
May 6, 2023
NCT07217015
NCT07298395
NCT06116526
NCT06461897
NCT07262983
NCT06389136
Lead Sponsor
Genentech, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions